The antiviral drug ganciclovir does not inhibit microglial proliferation and activation

Thomas Skripuletz1,*, Laura Salinas Tejedor1,2,*, Chittappen K. Prajeeth1, Florian Hansmann2,3, Chintan Chhatbar4, Valeria Kucman1, Ning Zhang2,3, Barbara B. Raddatz2,3, Claudia N. Detje4, Kurt-Wolfram Sühs5, Refik Pul1, Viktoria Gudi1, Ulrich Kalinke4, Wolfgang Baumgärtner2,3 & Martin Stangel1,2

Ganciclovir is effective in the treatment of human infections with viruses of the Herpesviridae family. Beside antiviral properties, recently ganciclovir was described to inhibit microglial proliferation and disease severity of experimental autoimmune encephalomyelitis, an inflammatory model of multiple sclerosis. Microglial activation and proliferation are main characteristics of neuroinflammatory CNS diseases and inhibition of microglial functions might be beneficial in autoimmune diseases, or detrimental in infectious diseases. The objective of this study was to determine potential inhibitory effects of ganciclovir in three different murine animal models of CNS neuroinflammation in which microglia play an important role: Theiler’s murine encephalomyelitis, the cuprizone model of de- and remyelination, and the vesicular stomatitis virus encephalitis model. In addition, in vitro experiments with microglial cultures were performed to test the hypothesis that ganciclovir inhibits microglial proliferation. In all three animal models, neither microglial proliferation nor recruitment nor disease activity was changed by ganciclovir. In vitro experiments confirmed that microglial proliferation was not affected by ganciclovir. In conclusion, our results show that the antiviral drug ganciclovir does not inhibit microglial activation and proliferation in the murine CNS.

Ganciclovir is currently used as an antiviral treatment for various human infections with viruses of the Herpesviridae family1,2. It remains the drug of choice for the prevention and treatment of cytomegalovirus (CMV) infection in transplant recipients1. The ability to inhibit virus replication requires intracellular phosphorylation by viral thymidine kinase to the triphosphate derivative, which is a competitive inhibitor of deoxyguanosine triphosphate thereby impaires viral DNA synthesis.

Recently, ganciclovir has been shown to have inhibitory functions on microglia and neuroinflammation in an inflammatory animal model of multiple sclerosis (MS)3. In murine myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE) ganciclovir strongly inhibited microglial proliferation, prevented T cell infiltration into the CNS, and strongly ameliorated disease severity in mice. Thus, ganciclovir was suggested as a potential novel therapeutic for neurological diseases associated with microglial proliferation and neuroinflammation.

The role of microglia in CNS neuroinflammation still remains unclear and beneficial as well as detrimental functions have been proposed. In general, activation of microglia is interpreted as a favorable inflammatory response to CNS infections where microglial derived cytokines are necessary to mount an effective immune response5. In CNS infectious diseases caused by herpes viruses such as CMV, inhibition...
of microglial functions thus might induce deleterious effects. For this reason, the aim of the present study was to determine possible inhibitory effects of ganciclovir on microglia by using three different murine models of CNS neuroinflammation in which microglia play an important role. We evaluated the effects of ganciclovir on microglia in Theiler’s murine encephalomyelitis (TME), the cuprizone model of de- and remyelination, and the vesicular stomatitis virus (VSV) encephalitis model. TME presents a virus-induced infection of the CNS and serves as an inflammation-mediated model of MS. The toxic cuprizone model of de- and remyelination, in which the induction of demyelination is achieved by cuprizone feeding, was used since in this model strong microglial activation occurs leading to clearance of myelin debris. VSV is a rhabdovirus that causes severe and rapid encephalitis accompanied by microgliosis in mice after intranasal infection. This virus has been shown to infect neuroepithelial cells, and hence is widely used as a model of acute neurotropic CNS infection. The aim of our experiments was to use different animal models that each mimics different aspects of the complex mechanisms in CNS neuroinflammation. To gain further insights on inhibitory effects of ganciclovir on microglial proliferation, in vitro experiments with murine microglial cultures were performed.

Results

Microglial proliferation is a prominent feature in animal models of CNS neuroinflammation. TME virus (TMEV) induced neuroinflammation is predominantly found in the hippocampus within the first weeks of infection. In our experiments, TMEV infection of mice was confirmed by immunohistochemical stainings of virus particles (Fig. 1A,B) and of T cell infiltration (Fig. 1C,D) in the hippocampus and total brain (data not shown). In this model, virus clearance is fast and only few infected cells could be detected after two weeks of infection (Fig. 1A,B). We found that TMEV infection is accompanied by prominent microglial proliferation and activation (Fig. 1E,F) as also previously observed by others. As compared to non-infected controls, significantly higher numbers of proliferating microglia (Iba1+/Ki67+) and total numbers of microglia (Iba1+) were found in the hippocampus. Proliferating microglia was detected in high numbers after one week of infection and decreased in numbers at week two.

In the toxic cuprizone model of de- and remyelination, oligodendrocytes are damaged within few days of cuprizone feeding and a nearly complete loss occurs after 3–4 weeks of treatment. Clearance of damaged myelin is conducted by microglial cells that are recruited towards areas of demyelination such as the corpus callosum and hippocampus. To demonstrate myelin loss, brain sections were immunohistochemically stained for the myelin protein proteolipid protein (PLP). As expected, after five weeks of cuprizone treatment a nearly complete demyelination of the corpus callosum (Fig. 2A) and hippocampus (data not shown) was visible. Withdrawal of cuprizone resulted in remyelination at week 6 as shown by the re-expression of the myelin protein PLP (Fig. 2A and data not shown). Demyelination was accompanied by high numbers of proliferating microglia (Iba1+/Ki67+) and total microglia numbers (Iba1+) in both regions (Fig. 2B,C). The amounts and dynamics of microgliosis have been reported to be different in both regions, which might be explained by the amount of myelin to be cleared.

In the hippocampus, numbers of proliferating microglia (Iba1+/Ki67+) and total microglia numbers (Iba1+) peaked at week 3 followed by a subsequent decrease. In the corpus callosum, higher numbers of microglial cells were found and microgliosis increased up to week 4 with subsequent decrease (Fig. 2B,C).

Intranasal infection with VSV in mice results in severe encephalitis accompanied by microgliosis. In our experiments, neuroinflammation was confirmed by immunohistochemical stainings for T cells in the cerebral cortex (Fig. 3A,C). After seven days of infection, an increase in the numbers of proliferating microglia (Iba1+/Ki67+) and total microglia numbers (Iba1+) was detectable in areas of inflammation (Fig. 3B,C).

No effects of ganciclovir on microglial proliferation and activation in vivo. As shown by immunohistochemical analyses, ganciclovir did not reduce numbers of proliferating microglia (Iba1+/Ki67+) and total numbers of microglia (Iba1+) neither during TMEV (Fig. 1E,F), nor during cuprizone induced demyelination and the subsequent remyelination (Fig. 2B,C), nor during VSV induced encephalitis (Fig. 3B,C). In the cuprizone and VSV model, there was a tendency towards higher numbers of proliferating microglia in ganciclovir treated animals, which was not significantly changed. Additional experiments by using BrdU confirmed that ganciclovir did not change numbers of proliferating microglia (Iba1+/BrdU+) during VSV induced encephalitis (data not shown). Thus, our results show that ganciclovir did not exert any inhibitory effects on microglia numbers in three animal models of neuroinflammation.

No effects of ganciclovir on neuroinflammation in vivo. Our experiments did not reveal any changes of ganciclovir on the course of CNS neuroinflammation in all three animal models analyzed in this study. In TMEV and VSV induced encephalitis, animals displayed similar T cell numbers in the brain (Figs 1C,D and 3A,C). In the cuprizone model, de- and remyelination followed the same pattern in the corpus callosum as well as in the hippocampus in both groups: ganciclovir treated animals and the corresponding controls (Fig. 2A).

No effects of ganciclovir on proliferation and viability of primary microglia in vitro. To determine whether ganciclovir might induce any cytotoxic effects on resting and activated microglia,
Figure 1. The effects of ganciclovir were investigated in Theiler’s murine encephalomyelitis virus (TMEV) infected C57BL/6 mice and in corresponding non-infected controls. Virus infection (A,B) and T cell infiltration (C,D) were confirmed by immunohistochemical stainings in the hippocampus. Total microglia numbers were analyzed by Iba1 staining, while proliferating microglia were visualized by double staining for Iba1/Ki67 (E,F). No effects of ganciclovir on virus infected neurons and T cell and microglial numbers could be observed between TMEV groups. Each bar represents the mean ± SEM, n = 6 per time point and group.
Figure 2. The effects of ganciclovir were investigated in the cuprizone model of de- and remyelination. After 5 weeks of cuprizone feeding, complete demyelination occurred as shown by the immunohistochemical staining for the myelin protein proteolipid protein (PLP) (A). One week after cuprizone withdrawal at week 6 remyelination was visible. Total microglia numbers were analyzed by Iba1 staining, while proliferating microglia were visualized by double staining for Iba1/Ki67 (B,C). No effects of ganciclovir on de- and remyelination and microglial numbers could be observed between cuprizone groups. Each bar represents the mean ± SEM, n = 6 per time point and group.
additional in vitro experiments were performed. First, the effects of ganciclovir on microglial proliferation were studied. Our results show that approximately 35% of microglia harvested from neonatal brain mixed glial cultures exhibited proliferation after re-plating, as demonstrated by incorporation of BrdU into these cells. Treatment with low doses of ganciclovir (0.05–0.1 mM) for 48 h did not have any impact on the proliferation of microglia (Fig. 4). At higher doses of ganciclovir (0.2–1 mM) a small decrease in the number of BrdU⁺ cells occurred, but this reduction did not yield a statistical significance (Fig. 4A,B).
We further studied the viability of microglia harvested from neonatal brain cultures in response to increasing doses of ganciclovir (0.01–1 mM) in the presence or absence of LPS. After 48 h microglia were stained for annexin V and PI and analyzed by flow cytometry. Irrespective of the activation state of microglia, we did not observe any significant difference in the percentage of annexin V+ (early apoptotic), annexin V+ PI+ (late apoptotic), and PI+ (necrotic) cells (Fig. 4C). In further experiments we tested the effects of ganciclovir after 72 h of treatment with ganciclovir and the results were similar (data not shown). Thus, our in vitro findings demonstrate that treatment with ganciclovir neither affected the survival nor had any significant effects on the proliferation of primary microglia. This is in accordance with our in vivo findings.

**Discussion**

Our experiments evaluated the effect of ganciclovir in different in vivo models of CNS neuroinflammation and in vitro cultures. Since a previous study reported the influence of ganciclovir on microglia, we specifically investigated the immunosuppressive activity on this glial cell type in other models of neuroinflammation. However, we did not observe a significant difference in numbers, proliferation rates, or cellular viability of microglia. Thus, we conclude that ganciclovir is not an inhibitor of microglial activation or proliferation.

In the work of Ding et al. (2014), ganciclovir drastically reduced EAE disease severity. Over the course of the disease, mice in the EAE control group suffered from hind limb paralysis and forelimb paresis, while ganciclovir treated animals only displayed loss of tail tone. The large difference between groups in disease severity persisted until the end of the observation period of 21 days. Thus, the authors suggested the substance ganciclovir as a potential novel therapeutic for neurological diseases associated with microglial proliferation and neuroinflammation. Since we could not find any effects of ganciclovir in three animal models of neuroinflammation, and because the experiments were even performed in three independent labs, we conclude that the effects of ganciclovir are limited to the EAE model and will rather not play a significant role in human diseases. In addition, the ganciclovir doses that induced inhibitory effects on neuroinflammation in EAE were very high for intraperitoneal injections with 25 and 100 mg ganciclovir per kg body weight. However, the parenteral doses used in humans for treatment of cytomegalovirus infection are lower and limited to a standard dose of 10 mg per day per kg body weight.

In our experiments we used a similar high dose of 25 mg ganciclovir per kg body weight in TMEV and cuprizone experiments. In VSV encephalitis we even used a higher dose of 50 mg ganciclovir per kg body weight. Since the experiments based on comparable drug doses among the EAE and our animal models, we suggest that the assessed ganciclovir effect is dose independent. The pharmacokinetics
of ganciclovir in plasma and CNS were studied in animals including primates as well as in humans and it was shown that ganciclovir penetrates into the CSF in both inflammatory and resting conditions with an intact blood-brain-barrier. Thus, it can be assumed that ganciclovir reached sufficient concentrations in all animal models used in our study. Furthermore, we have shown previously that the administered ganciclovir regimen is biologically active and efficient to deplete astrocytes in the cuprizone model in transgenic mice that express the herpes simplex thymidine kinase under the GFAP promoter. Limitations of our study are small animal numbers and the lack of functional assays which is difficult in the three models used.

The reason for the contrary findings might be explained by the pathophysiological differences in the animal models. Peripheral immune cells and especially T cells play a key role in EAE induction and it was shown that T cells reside within the bronchus-associated lymphoid tissue of the lungs where priming takes place before entering the CNS. Thus, it might be speculated that ganciclovir there exert its immune modulatory functions on immune cells that could inhibit their migration towards the CNS. Consequently, when treatment with ganciclovir was started after the EAE mice reached a high disease score of 2 corresponding to hind limb weakness or paresis, disease severity was not significantly changed.

Interestingly, the effects of ganciclovir in EAE were already tested in transgenic GFAP-TK mice, in which the treatment with ganciclovir leads to loss of reactive astrocytes. In this work, transgenic mice that were treated with ganciclovir exhibited a severe clinical course of EAE and higher numbers of Iba1+ cells in the white and grey matter of the CNS as compared to controls without ganciclovir treatment. However, the high numbers of Iba1+ cells are most probably a consequence of astrocyte ablation and thus the comparison of these results have some limitations. Toft-Hansen et al. demonstrated higher numbers of infiltrating macrophages into the CNS of ganciclovir treated GFAP-TK transgenic mice as well. In this work, additional controls included wildtype C57BL/6 mice that were treated with ganciclovir or sham beginning on the first day when each mouse presented definite EAE symptoms. Treatment with ganciclovir did not show any effects on numbers of macrophages/microglia and neuroinflammation during EAE.

Ganciclovir presents an important drug for the treatment of cytomegalovirus infections in humans. However, due to its high toxicity its role is rather limited in human herpes simplex and varicella zoster infections, and acyclovir is preferentially used. Even if there would be an effect on microglial proliferation and neuroinflammation in humans, we conclude that ganciclovir would not play an important role in human autoimmune disorders such as multiple sclerosis.

Methods
Experimental design. The objective of the study was to determine the effects of the drug ganciclovir on microglial proliferation and activation by using three different murine animal disease models of CNS neuroinflammation and in vitro experiments. Analyses were performed using two animal models of MS (TME and cuprizone) and a murine model of acute encephalitis induced by intranasal infection of the vesicular stomatitis virus (VSV). In vitro experiments were performed by using murine microglia. The ganciclovir (Cymevene, Roche) used was previously shown by us to be biologically active and efficient to deplete astrocytes in transgenic mice

Animals. Animal experiments were performed in three independent labs (TMEV infection experiments at the University of Veterinary Medicine Hannover, cuprizone experiments at Hannover Medical School, and VSV infection experiments at the Institute for Experimental Infection Research TWINCORE Hannover). For all animals, food and water were available ad libitum. All research and animal care procedures were approved by the review board for the care of animal subjects of the district government and performed according to international guidelines on the use of laboratory animals.

Theiler's murine encephalomyelitis infection and ganciclovir treatment protocol. For TME, five-week-old female C57BL/6 mice (Harlan) were infected intracerebrally with 20 μl containing 1.14 × 10^5 PFU/mouse of the BeAn strain of TMEV or mock (vehicle only) under general anesthesia using a combination of medetomidine and ketamine as previously described. Animals were treated with ganciclovir (25 mg per kg) intraperitoneally or sham every day beginning on the day of infection until termination of the experiment. The four groups included (I) TMEV infected mice and treated with ganciclovir; (II) TMEV infected mice and treated with sham; (III) mock infected mice and treated with ganciclovir; (IV) mock infected mice and treated with sham. After 1 week and 2 weeks of infection mice were transcardially perfused with phosphate buffer. Brains of the four groups were removed and fixed in 4% buffered formaldehyde. A group size of six animals was analysed at each time point.

Cuprizone induced demyelination and ganciclovir treatment protocol. Experimental toxic demyelination was induced by feeding eight-week-old male C57BL/6 mice (Jackson Laboratory) a diet containing 0.2% cuprizone (bis-cyclohexane oxalldihydrazone, Sigma-Aldrich) mixed into a ground standard rodent chow. The cuprizone diet was maintained for 5 weeks. Animals were treated with ganciclovir (25 mg per kg) intraperitoneally or sham every day beginning on the day of cuprizone feeding until termination of the experiment. A group size of six animals was analysed at each time point (week 3, 4,
and 5 for demyelination, week 6 for remyelination). Mice were perfused with 4% paraformaldehyde in phosphate buffer through the left cardiac ventricle and brains were removed as described.

**Vesicular stomatitis virus infection and ganciclovir treatment protocol.** For VSV infection, twelve-week-old female C57BL/6 mice were purchased from Harlan-Winkelmann (Borchen). Prior infection, mice were anesthetized with ketamine/xylazine and a total of 10 μl containing 10^6 PFU of VSV in PBS were pipetted into both nostrils. In order to investigate anti-inflammatory effects of ganciclovir, a group of VSV infected mice was treated with ganciclovir intraperitoneally or sham for controls every day beginning on day 1 p.i. at a dose of 50 mg/kg. On day 7, mice were perfused with 4% formaldehyde in saline and brains were removed. In an additional experiment BrdU (10 μl/g, Life Technologies) was applied every day beginning on the day of VSV infection until termination on day 7.

**Immunohistochemistry.** Immunohistochemistry was performed as previously described. Brains were removed, postfixed in 4% PFA and paraffin embedded. For immunohistochemistry the following primary antibodies were used: for myelination the proteolipid protein (PLP) (mouse IgG, 1:500, Sigma-Tau), for microglia Ionized calcium-binding adaptor molecule 1 (Iba-1; rabbit anti-Iba-1, 1:1000, Wako), for T cells (rabbit IgG, 1:500, Dako), for proliferation Ki67 (mouse IgG, 1:50, BD Pharmingen) and BrdU (mouse IgG, 1:200, Roche diagnostics GmbH). Immunohistology targeting TMEV was performed using an anti-TMEV antibody (polyclonal rabbit anti-TMEV capsid protein VP1, 1:2000).

**Quantification of glial reactions.** In TMEV infected and cuprizone treated animals brain sections between bregma +0.82 mm and bregma −1.82 mm were analysed. For VSV encephalitis experiments, brain sections between bregma +4.28 mm and bregma +3.92 mm were analysed. Quantification of glial cells was performed for proliferating microglia (double staining with Iba1/Ki67) and the total microglial numbers (Iba1). Immunopositive cells with identified nucleus (counterstaining with Mayer’s haemalum solution for immunohistochemistry or 4',6-diamidino-2-phenylindole (DAPI) for immunofluorescence) were counted in the hippocampus of TMEV infected and cuprizone fed mice and their corresponding controls using a magnification of ×200 (Olympus BX61). In addition, in the cuprizone model cells were counted in the central part of the corpus callosum as previously described. In results counted cells are expressed as number of cells per mm². The extent of demyelination in the corpus callosum of cuprizone fed mice was analysed by light microscopy (Olympus BX61) as described previously. For determination of demyelination in the corpus callosum PLP stained brain sections were scored in a blinded manner by three observers and graded on a scale from 0 (complete demyelination) to 3 (normal myelin).

**Microglia cell culture.** Primary cultures of microglia were prepared from neonatal C57BL/6 murine brains as previously described. The mixed glial cells obtained from brains were seeded into poly-L-lysine-coated T75mm² culture flasks in medium consisting of DMEM + 4% formaldehyde in saline and brains were removed as described. Life Technologies) was applied every day beginning on the day of VSV infection until termination on day 7.

**Microglia proliferation assay.** Microglia proliferation was measured by the detection of 5-bromo-20-deoxyuridine (BrdU) (Roche diagnostics GmbH) incorporation into the DNA. Microglia were treated with increasing concentrations of ganciclovir (0.05–1 mM) in the presence or absence of LPS (100 ng/ml; E. coli 055:B5; Sigma-Aldrich) and incubated for 48 h. BrdU (10 μM) was added to the medium for the last 24 h. Cells were fixed with 4% paraformaldehyde and stainings for microglia (Iba1, Wako) and BrdU were performed as previously described. Labelled cells were analysed using a fluorescence microscope and proliferation index was calculated by dividing number of BrdU-positive cells with total number of Iba1 positive cells.

**Annexin V and PI staining.** Cell death and apoptotic cells were assessed by using FITC Annexin V apoptosis detection kit I (BD Pharmingen). Microglia harvested from mixed glial preparations as mentioned above were plated in 12-well plates at 2.5 × 10⁴ cells per well and treated with different concentrations of ganciclovir (0.01–1 mM) for 48 h. Subsequently, microglia were harvested with Trypsin-EDTA (Biochrom) and stained with FITC Annexin V and propidium iodine (PI). Staining was performed according to the instructions provided by the manufacturer. After staining, cells were analyzed on a FACS calibur (BD Biosciences).

**Statistical analysis.** Statistical analysis was performed using ANOVA followed by the Fisher-protected least-significant difference test for post hoc comparison if appropriate. P values are given in the results while group comparisons derived from post hoc analysis are provided in the figures (* P < 0.05; **P < 0.01; ***P < 0.001).
References

1. Skorecki, M. & Sienczyk, M. Anti-herpesvirus agents: a patent and literature review (2003 to present). Expert Opin. Ther. Pat. 24, 925–941 (2014).

2. Stockmann, C., Roberts, J. K., Knackstedt, E. D., Spigarelli, M. G. & Sherwin, C. M. Clinical pharmacokinetics and pharmacodynamics of ganciclovir and valganclovir in children with cytomegalovirus infection. Expert Opin. Drug Metab. Toxicol. 11, 205–219 (2015).

3. Scott, J. C., Partovi, N. & Ensom, M. H. Ganciclovir in solid organ transplant recipients: is there a role for clinical pharmacokinetic monitoring? Ther. Drug Monit. 26, 68–77 (2004).

4. Ding, Z. et al. Antiviral drug ganciclovir is a potent inhibitor of microglial proliferation and neuroinflammation. J. Exp. Med. 211, 189–198 (2014).

5. Turrin, N. P. & Rivest, S. Tumor necrosis factor alpha but not interleukin 1 beta mediates neuroprotection in response to acute nitric oxide excitotoxicity. J. Neurosci. 26, 143–151 (2006).

6. Hansmann, F. et al. Matrix metalloproteinase-12 deficiency ameliorates the clinical course and demyelination in Thielers murine encephalomyelitis. Acta Neuropathol. 124, 127–142 (2012).

7. Skripuletz, T. et al. Pivotal role of choline metabolites in remyelination. Brain 138, 398–413 (2015).

8. Skripuletz, T. et al. Astrocytes regulate myelin clearance through recruitment of microglia during cuprizone-induced demyelination. Brain 136, 147–167 (2013).

9. Voss, E. V. et al. Characterisation of microglia during de- and remyelination: Can they create a repair promoting environment? Neurobiol. Dis. 45, 519–528 (2012).

10. Bi, Z., Barma, M., Komatsu, T. & Reiss, C. S. Vesicular stomatitis virus infection of the central nervous system activates both innate and acquired immunity. J. Virol. 69, 6466–6472 (1995).

11. Detej, C. N. et al. Local type I IFN receptor signaling protects against virus spread within the central nervous system. J. Immunol. 182, 2297–2304 (2009).

12. Chauhan, V. S. et al. Vesicular stomatitis virus infects resident cells of the central nervous system and induces replication-dependent inflammatory responses. Virology 400, 187–196 (2010).

13. Kummerfeld, M. et al. Periventricular demyelination and axonal pathology is associated with subependymal virus spread in a murine model for multiple sclerosis. Intervirology 55, 401–416 (2012).

14. Herder, V. et al. Interleukin-10 expression during the acute phase is a putative prerequisite for delayed viral elimination in a murine model for multiple sclerosis. J. Neuroimmunol. 249, 27–39 (2012).

15. Safari, M. et al. Impact of Thielers virus infection on hippocampal neuronal progenitor cells: differential effects in two mouse strains. Neuropathol. Appl. Neurobiol. 38, 647–664 (2012).

16. Lipton, H. L. Thielers virus infection in mice: an unusual biphasic disease process leading to demyelination. Infect. Immun. 11, 1147–1155 (1975).

17. Skripuletz, T. et al. Lipopolysaccharide delays demyelination and promotes oligodendrocyte precursor proliferation in the central nervous system. Brain Behav. Immun. 25, 1592–1606 (2011).

18. Gudi, V. et al. Regional differences between grey and white matter in cuprizone induced demyelination. Brain Res. 1283, 127–138 (2009).

19. Norkute, A. et al. Cuprizone treatment induces demyelination and astrocytosis in the mouse hippocampus. J. Neurosci. Res. 87, 1343–1355 (2009).

20. Koutsoudaki, P. N. et al. Demyelination of the hippocampus is prominent in the cuprizone model. Neurosci. Lett. 451, 83–88 (2009).

21. Serabe, B. M. et al. Plasma and CSF pharmacokinetics of ganciclovir in nonhuman primates. Cancer. Chemother. Pharmacol. 43, 415–418 (1999).

22. Fletcher, C., Sawchuk, R., Chinnock, B., de Miranda, P. & Balfour, H. H. Jr. Human pharmacokinetics of the antiviral drug DHPG. Clin. Pharmacol. Ther. 40, 281–286 (1986).

23. Nau, R., Sorgel, F. & Effert, H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin. Microbiol. Rev. 23, 858–883 (2010).

24. Odoardi, F. et al. T cells become licensed in the lung to enter the central nervous system. J. Neuroimmunol. 1147–1155 (1975).

25. Voss, E. V. et al. Antibody therapy for the detection of Theiler's murine encephalomyelitis virus by light and electron microscopy. J. Virol. Methods 185–188 (2015).

26. Toft-Hansen, H., Fuchtbauer, L. & Owens, T. Inhibition of reactive astrocytosis in established experimental autoimmune encephalomyelitis favors infiltration by myeloid cells over T cells and enhances severity of disease. Glia, 59, 166–176 (2011).

27. Herder, V. et al. Cuprizone inhibits demyelinating leukomyelitis by reducing immune responses without virus exacerbation in an infectious model of multiple sclerosis. J. Neuroimmunol. 244, 84–93 (2012).

28. Kummerfeld, M., Meens, J., Haas, L., Baumgartner, W. & Beineke, A. Generation and characterization of a polyclonal antibody for the detection of Thielers murine encephalomyelitis virus by light and electron microscopy. J. Virol. Methods. 160, 185–188 (2009).

29. Skripuletz, T. et al. Cortical demyelination is prominent in the murine cuprizone model and is strain-dependent. Am. J. Pathol. 172, 1053–1061 (2008).

30. Prayoth, C. K. et al. Effector molecules released by Th1 but not Th17 cells drive an M1 response in microglia. Brain Behav. Immun. 37, 248–259 (2014).

31. Singh, V., Voss, E. V., Benardais, K. & Stangel, M. Effects of 2-chlorodeoxyadenosine (Cladribine) on primary rat microglia. J. Neuroimmune Pharmacol. 7, 939–950 (2012).

Acknowledgements

We thank I. Cierpka-Leja, S. Lang, A. Niesel, C. Schütz, and P. Grünig for excellent technical assistance. The BeAn strain of TMEV was a generous gift of Prof. H.L. Lipton, Department of Microbiology–Immunology, University of Illinois, Chicago, USA. TS is supported by the Genzyme Neuroimmunology Fellowship. TS, MS, and WB are supported by the German Research Foundation (DFG, FOR 1103, TP1b). MS, WB, and UK are supported by the Niedersachsen Research Network on Neuroinfectiology (N-RENNT) of the Ministry of Science and Culture of Lower Saxony. CC, MS, and UK are supported by a bilateral project of the German Centre for Neurodegenerative Diseases and the Helmholtz Centre for Infection Research (to MS and UK).
Author Contributions
T.S., L.S.T. and M.S. conceived the experiments. W.B., F.H., N.Z. and B.R. performed the TMEV experiments. L.S.T., V.K., V.G., R.P. and K.W.S. performed the cuprizone experiments. C.C., C.D. and U.K. performed the VSV encephalitis experiments. C.K.P. performed the in vitro experiments. T.S., L.S.T. and M.S. wrote the manuscript.

Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Skripuletz, T. et al. The antiviral drug ganciclovir does not inhibit microglial proliferation and activation. Sci. Rep. 5, 14935; doi: 10.1038/srep14935 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/